Amicus Therapeutics Inc (AM6 F) stock market data APIs
€12.0503
0.16(1.3%)
as of January 19, 2026
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
12.0503
Open
12.2082
High
12.2256
Low
12.0196
52 wk Range
4.8-12.3
Market Cap
3 768 M
Shares Outstanding
309 M
Revenue
599 M
EPS
-0.19
Beta
0.415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 599 M
- EBITDA: 42 120 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus
Last Friday, the three most widely followed benchmark indexes closed a losing week. The Dow Jones Industrial Average, the S&P 500 and the Nasdaq Composite declined roughly 0.3%, 0.4% and 0.7%, respect...
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum
Amicus Therapeutics (FOLD) has been drawing fresh attention after a strong recent share move, with the stock up about 46% over the past month and roughly 72% in the past 3 months. See our latest anal...
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential
If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value right now, this article walks through the key signals that matter for long term investors. The stock has rece...
When healthcare M&A hits the cold chain
The $4.8 billion acquisition of Amicus Therapeutics by BioMarin is, on its surface, a familiar healthcare story: portfolio expansion, accelerated revenue growth, and a stronger foothold in the rare di...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
